

Figure 1






Figure 2



Fab PRIT-0213






FIG. 3

Figure 4



^{203}Pb -DOTAM-bsAb biodistribution (s.c. BxPC3 model)






Figure 7

²¹²Pb-CA biodistribution (s.c. MKN45 model) 2 h p.i.




Figure 8

²¹²Pb-CA biodistribution (s.c. MKN45 model) 24 h p.i.




Figure 9

²¹²Pb-CA biodistribution (s.c. MKN45 model) 24 h p.i.




Figure 10

²⁰³Pb-CA biodistribution in tumor-free mice, 1 week p.i.




Figure 11




Figure 12

²¹²Pb-DOTAM content in blood, 4 h p.i.




Figure 13

²¹²Pb-DOTAM content in blood, 24 h p.i.




Figure 14

²¹²Pb-DOTAM tumor uptake (s.c. BxPC3)




Figure 15




Figure 16

^{212}Pb -DOTAM biodistribution (s.c. BxPC3 model)




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24

PRIT-0213-0214 repeated treatment efficacy in BxPC3




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31




Figure 32




Figure 33




Figure 34




Figure 35




Figure 36





Figure 37: Possible antibody formats






Figure 38: Binding of P1AD8927 to KPL-4 cells to demonstrate Her2 binding competence: Detection of antibodies using human IgG specific secondary antibodies




Figure 39: Binding of P1AD8927 to KPL-4 cells to demonstrate DOTAM binding competence: Isotypecorrected detection using Pb-DOTAM-FITC




Figure 40: Binding of P1AD8926 to Raji cells to demonstrate CD20 binding competence: Detection of antibodies using human IgG specific secondary antibodies





Figure 41: Binding of P1AD8926 to Raji cells to demonstrate DOTAM binding competence: Isotypecorrected detection using Pb-DOTAM-FITC



Design of Protocol 103

FIG. 42

Figure 43: In Vivo Radioactivity Distribution 24 Hours after ²¹²Pb-DOTAM Injection (Treatment Cycle 1 and 2)




Figure 44: Tumor Development after CEA PRIT in the BxPC3 Model




Figure 45: Individual Tumor Growth Curves after CEA PRIT in the BxPC3 Model




Figure 46: Survival after CEA PRIT in the BxPC3 Model




Figure 47: Average Body Weight Change after CEA PRIT in the BxPC3 Model




Figure 48: 203Pb-BsAb Distribution in SCID Mice Bearing SC BxPC3 Tumors




Figure 49: 203Pb-BsAb BxPC3 Tumor Accumulation in SCID Mice






Figure 50: Biodistribution of Pretargeted 212Pb-DOTAM in SCID Mice Carrying SC BxPC3 Tumors





Design of Protocol 131
FIG. 51

Figure 52: Biodistribution of Pretargeted 212Pb-DOTAM in SCID Mice Carrying SC BxPC3 Tumors (2 h p.i.)




Figure 53: Distribution of 212Pb-DOTAM in Selected Normal Tissues (2 h p.i.)




Figure 54: Biodistribution of Pretargeted 212Pb-DOTAM in SCID Mice Carrying SC WSU-DLCL2 Tumors (24 h p.i.)






Figure 55: Biodistribution of Pretargeted 212Pb-DOTAM in SCID Mice Carrying SC NCI-N87 Tumors (24 h p.i.)





Design of Protocol 154
FIG. 56

Figure 57: Biodistribution of Pretargeted 212Pb-DOTAM in SCID Mice Carrying SC HPAF-II Tumors (6 h p.i.)






Figure 58: Accumulation of Pretargeted 212Pb-DOTAM in HPAF-II Tumors





Experimental schedule of protocol 162

FIG. 59

Figure 60: Biodistribution of pretargeted 212Pb-DOTAM and 212Pb-DOTAM-CD20-DOTAM in SCID mice carrying SC WSU-DLCL2 tumors (24 h p.i.)




Figure 61: Average SC WSU-DLCL2 tumor volumes in SCID mice treated with CD20-targeted therapies or negative controls




Figure 62: Average body weight development in SCID mice treated with CD20-targeted therapies or negative controls

